Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine.

[1]  Q. Lan,et al.  Differentiation profile of brain tumor stem cells: a comparative study with neural stem cells , 2006, Cell Research.

[2]  G. Thomas,et al.  The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases , 1996, Molecular and cellular biology.

[3]  C. Antonescu,et al.  Midline carcinoma of children and young adults with NUT rearrangement. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Mandrekar,et al.  A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies , 2006, Cancer Chemotherapy and Pharmacology.

[5]  T. Vanhaecke,et al.  Differential role of epigenetic modulators in malignant and normal stem cells: a novel tool in preclinical in vitro toxicology and clinical therapy , 2007, Archives of Toxicology.

[6]  D. Ribatti,et al.  Combined Therapeutic Effects of Vinblastine and Rapamycin on Human Neuroblastoma Growth, Apoptosis, and Angiogenesis , 2007, Clinical Cancer Research.

[7]  D. Sabatini,et al.  Structure of S6 Kinase 1 Determines whether Raptor-mTOR or Rictor-mTOR Phosphorylates Its Hydrophobic Motif Site*♦ , 2005, Journal of Biological Chemistry.

[8]  G. Moreno-Bueno,et al.  Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis , 2007, Oncogene.

[9]  T. Vogt,et al.  Anti‐inflammatory and angiostatic therapy in chemorefractory multisystem Langerhans’ cell histiocytosis of adults , 2005, British journal of haematology.

[10]  J. B. Park,et al.  Phospholipase D1 is located and activated by protein kinase C alpha in the plasma membrane in 3Y1 fibroblast cell. , 1999, Biochimica et biophysica acta.

[11]  M. Tabata,et al.  Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons. , 2002, Current pharmaceutical design.

[12]  Robert E. Brown,et al.  Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. , 2006, Annals of clinical and laboratory science.

[13]  U. Ullmann,et al.  Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein™) in healthy volunteers , 2005, Advances in therapy.

[14]  K. Black,et al.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.

[15]  S. Inoue,et al.  Survival versus apoptotic 17β‐estradiol effect: Role of ERα and ERβ activated non‐genomic signaling , 2005, Journal of cellular physiology.

[16]  A. Sacchi,et al.  Insulin Receptor Substrate-1, p70S6K, and Cell Size in Transformation and Differentiation of Hemopoietic Cells* , 2000, The Journal of Biological Chemistry.

[17]  F. Westermann,et al.  Histone deacetylase inhibitor Helminthosporium carbonum (HC)‐toxin suppresses the malignant phenotype of neuroblastoma cells , 2007, International journal of cancer.

[18]  S. Bose,et al.  The Akt pathway in human breast cancer: a tissue-array-based analysis , 2006, Modern Pathology.

[19]  B. Aggarwal,et al.  Anticancer potential of curcumin: preclinical and clinical studies. , 2003, Anticancer research.

[20]  Eric S Manas,et al.  Understanding the selectivity of genistein for human estrogen receptor-beta using X-ray crystallography and computational methods. , 2004, Structure.

[21]  C. Kahn,et al.  Insulin stimulates p70 S6 kinase in the nucleus of cells. , 1997, Biochemical and biophysical research communications.

[22]  Robert E. Brown.  Brief communication: morphoproteomic analysis of osteolytic Langerhans cell histiocytosis with therapeutic implications. , 2005, Annals of clinical and laboratory science.

[23]  G. Sheu,et al.  Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. , 2004, European journal of pharmacology.

[24]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[25]  Syed Mohsin,et al.  Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  H. Seo,et al.  Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts. , 2005, Molecular endocrinology.

[27]  I. Bièche,et al.  Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines , 2008, Cancer Chemotherapy and Pharmacology.

[28]  T. Naoe,et al.  Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy , 1999, Leukemia.

[29]  R. Frey,et al.  Genistein activates p38 mitogen-activated protein kinase, inactivates ERK1/ERK2 and decreases Cdc25C expression in immortalized human mammary epithelial cells. , 2003, The Journal of nutrition.

[30]  Chang Gun Kim,et al.  Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. , 2008, Cancer letters.

[31]  S. Andò,et al.  Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. , 2001, Molecular pharmacology.

[32]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Robert E. Brown,et al.  Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients , 2005, Expert review of proteomics.

[34]  Shaobo Zhu,et al.  Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma. , 2006, Annals of clinical and laboratory science.

[35]  Targeting metastatic leiomyosarcoma by rapamycin plus gemcitabine: an intriguing clinical observation. , 2004, International journal of molecular medicine.

[36]  C. Petritsch,et al.  Cell Cycle Regulation of p70 S6 Kinase and p42/p44 Mitogen-activated Protein Kinases in Swiss Mouse 3T3 Fibroblasts (*) , 1996, The Journal of Biological Chemistry.

[37]  J. Heitman,et al.  Expression, enzyme activity, and subcellular localization of mammalian target of rapamycin in insulin-responsive cells. , 1997, Biochemical and biophysical research communications.

[38]  I. Mellinghoff,et al.  Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer , 2006, Nature Medicine.

[39]  A. Fernández,et al.  Nuclear localization of p85s6k: functional requirement for entry into S phase. , 1994, The EMBO journal.

[40]  M. Diederich,et al.  Regulation of glutathione S-transferase P1-1 gene expression by NF-kappaB in tumor necrosis factor alpha-treated K562 leukemia cells. , 2004, Biochemical pharmacology.

[41]  I. Beis,et al.  ERK1/2 and p38-MAPK signalling pathways, through MSK1, are involved in NF-kappaB transactivation during oxidative stress in skeletal myoblasts. , 2006, Cellular signalling.

[42]  Robert E. Brown,et al.  Morphoproteomic and pharmacoproteomic correlates in hormone-receptor-negative breast carcinoma cell lines. , 2004, Annals of clinical and laboratory science.

[43]  K. Matsushima,et al.  Induction and regulation of IL-8 and MCAF production in human brain tumor cell lines and brain tumor tissues. , 1993, European cytokine network.

[44]  H. Yamamoto,et al.  Inhibitory effect of curcumin on mammalian phospholipase D activity , 1997, FEBS letters.

[45]  J. Soutschek,et al.  Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel , 2007, Anti-cancer drugs.

[46]  Xianglin Shi,et al.  G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. , 2004, American journal of physiology. Cell physiology.

[47]  R. Dahiya,et al.  Retracted: Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells , 2008, International journal of cancer.

[48]  Malcolm R. Alison,et al.  Stem cells and cancer: a deadly mix , 2007, Cell and Tissue Research.

[49]  W. Weichert,et al.  High expression of RelA/p65 is associated with activation of nuclear factor-κB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis , 2007, British Journal of Cancer.

[50]  G. Thomas,et al.  p70s6k/p85s6k: mechanism of activation and role in mitogenesis. , 1994, Seminars in cancer biology.

[51]  S. Wilhelm,et al.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.

[52]  D. Alessi,et al.  Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. , 1999, The Biochemical journal.

[53]  In-Hyun Park,et al.  A Nuclear Transport Signal in Mammalian Target of Rapamycin Is Critical for Its Cytoplasmic Signaling to S6 Kinase 1* , 2006, Journal of Biological Chemistry.

[54]  K. Heuner,et al.  Mechanisms of Legionella pneumophila-induced interleukin-8 expression in human lung epithelial cells , 2007, BMC Microbiology.

[55]  M. Andjelkovic,et al.  Phosphorylation and activation of p70s6k by PDK1. , 1998, Science.

[56]  Robert E. Brown,et al.  Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia. , 2004, Annals of clinical and laboratory science.

[57]  H. McLeod,et al.  Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. , 2004, International journal of oncology.

[58]  S. Fulda,et al.  Activation of Akt predicts poor outcome in neuroblastoma. , 2007, Cancer research.

[59]  D. Qian,et al.  Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589 , 2006, Clinical Cancer Research.

[60]  J. Raizer,et al.  Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Robert E. Brown,et al.  Overexpression of phosphorylated nuclear factor-kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis , 2005, Modern Pathology.

[62]  James B. Mitchell,et al.  Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. , 2005, International journal of radiation oncology, biology, physics.

[63]  M. Pagano,et al.  S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. , 2002, The American journal of pathology.

[64]  H. Friess,et al.  Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. , 2006, The Journal of surgical research.

[65]  Marty W. Mayo,et al.  Akt Stimulates the Transactivation Potential of the RelA/p65 Subunit of NF-κB through Utilization of the IκB Kinase and Activation of the Mitogen-activated Protein Kinase p38* , 2001, The Journal of Biological Chemistry.

[66]  F. Sarkar,et al.  Genistein inhibits radiation-induced activation of NF-κB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest , 2006, BMC Cancer.

[67]  G. Haegeman,et al.  Transcriptional activation of the NF‐κB p65 subunit by mitogen‐ and stress‐activated protein kinase‐1 (MSK1) , 2003, The EMBO journal.

[68]  D. McConkey,et al.  Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells , 2006, Molecular Cancer Therapeutics.

[69]  X. Guan,et al.  CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway , 2008, Oncogene.

[70]  Joseph Avruch,et al.  Regulation of the p70 S6 Kinase by Phosphorylation in Vivo , 1998, The Journal of Biological Chemistry.

[71]  R. Stote,et al.  Histone H3 Tails Containing Dimethylated Lysine and Adjacent Phosphorylated Serine Modifications Adopt a Specific Conformation during Mitosis and Meiosis , 2008, Molecular and Cellular Biology.

[72]  J. Ajani,et al.  Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  L. Mcphail,et al.  Phospholipase D2‐derived phosphatidic acid binds to and activates ribosomal p70 S6 kinase independently of mTOR , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[74]  G. Mills,et al.  Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells , 2004, Clinical Cancer Research.

[75]  S. Ferrari,et al.  S6 phosphorylation and the p70s6k/p85s6k. , 1994, Critical reviews in biochemistry and molecular biology.

[76]  Wainer Zoli,et al.  Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: A cytometric study , 2006, BMC Cell Biology.